Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Welch

Showing results (391-400 of 422) with videos related to

Pageof 43
Sort By:
International Journal of Molecular Sciences|November 27, 2021
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB)Peter W Jurutka, Orsola di Martino, Sabeeha Reshi, et al.
The New England Journal of Medicine|November 1, 2018
Immune Escape of Relapsed AML Cells after Allogeneic TransplantationMatthew J Christopher, Allegra A Petti, Michael P Rettig, et al.
International Journal of Molecular Sciences|December 23, 2022
An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than BexarotenePeter W Jurutka, Orsola di Martino, Sabeeha Reshi, et al.
Blood Cancer Discovery|June 16, 2022
Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome ProgressionAndrew J Menssen, Ajay Khanna, Christopher A Miller, et al.
Journal of Medicinal Chemistry|September 1, 2023
Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC)Adrian D Hobson, Jianwen Xu, Dennie S Welch, et al.
BMJ Oncology|April 1, 2026
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trialsJ Randolph Hecht, Julian R Molina, Kirstin Liechty, et al.
Leukemia|October 4, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment responseMeagan A Jacoby, Eric D Duncavage, Ajay Khanna, et al.
Ebiomedicine|August 1, 2022
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimeraAmy S Espeseth, Maoli Yuan, Michael Citron, et al.
Current Oncology (Toronto, Ont.)|November 12, 2019
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018A J Hyde, R Nassabein, A AlShareef, et al.
JCO Precision Oncology|May 26, 2021
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid LeukemiaErica K Barnell, Kenneth F Newcomer, Zachary L Skidmore, et al.
Pageof 43

Showing results (391-400 of 422) with videos related to

Sort By:
Pageof 43
International Journal of Molecular Sciences|November 27, 2021
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB)Peter W Jurutka, Orsola di Martino, Sabeeha Reshi, et al.
The New England Journal of Medicine|November 1, 2018
Immune Escape of Relapsed AML Cells after Allogeneic TransplantationMatthew J Christopher, Allegra A Petti, Michael P Rettig, et al.
International Journal of Molecular Sciences|December 23, 2022
An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than BexarotenePeter W Jurutka, Orsola di Martino, Sabeeha Reshi, et al.
Blood Cancer Discovery|June 16, 2022
Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome ProgressionAndrew J Menssen, Ajay Khanna, Christopher A Miller, et al.
Journal of Medicinal Chemistry|September 1, 2023
Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC)Adrian D Hobson, Jianwen Xu, Dennie S Welch, et al.
BMJ Oncology|April 1, 2026
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trialsJ Randolph Hecht, Julian R Molina, Kirstin Liechty, et al.
Leukemia|October 4, 2024
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment responseMeagan A Jacoby, Eric D Duncavage, Ajay Khanna, et al.
Ebiomedicine|August 1, 2022
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimeraAmy S Espeseth, Maoli Yuan, Michael Citron, et al.
Current Oncology (Toronto, Ont.)|November 12, 2019
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018A J Hyde, R Nassabein, A AlShareef, et al.
JCO Precision Oncology|May 26, 2021
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid LeukemiaErica K Barnell, Kenneth F Newcomer, Zachary L Skidmore, et al.
Pageof 43